G
G-Flas
Develops and manufactures products for the health and well-being of people
About G-Flas
GFLAS is a pioneering company in the field of CRISPR-based genome editing, offering advanced solutions for both research and therapeutic applications. The company specializes in the development and application of CRISPR CasN enzymes, which are used to precisely modify genetic material. GFLAS serves a diverse range of clients, including academic research institutions, biotechnology firms, and pharmaceutical companies, operating primarily in the biotechnology and life sciences markets.
The business model of GFLAS revolves around providing high-quality CRISPR products and services. This includes custom CRISPR CasN enzyme synthesis, genome editing services, and intellectual property licensing. The company generates revenue through the sale of these products and services, as well as through strategic partnerships and collaborations with other entities in the biotech sector.
GFLAS leverages its proprietary CRISPR technology to offer tailored solutions that meet the specific needs of its clients. By focusing on innovation and quality, the company aims to drive advancements in genetic research and therapeutic development. GFLAS's commitment to excellence is reflected in its robust R&D efforts and its collaborations with leading organizations in the field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Seoul, South Korea
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 35.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Farming, Oncology, Drug Development, Crispr, Gene Therapy, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Jun 2022 | $2.5M | $10M | SmileGate Investment | — |
| LATE VCOther financing | May 2021 | $235K | $939K | Undisclosed | — |
Growth signals
Latest recorded traffic for G-Flas is 430 monthly website visits, down 91.4% over the last three months. G-Flas's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
DS Asset Management- TMTimefolio Asset Management
Series B and later3 investors entered at this stage
New Flight
SmileGate Investment- AMAlpenroute Asset Management
Other known investors3 additional known investors
Seoul National University
ActnerLab- E&E&Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about G-Flas on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See G-Flas’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.